Progenics Pharmaceuticals
(PGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2011 | 03-2011 | 12-2010 | 09-2010 | 06-2010 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 32,559 | -22,927 | -69,725 | -50,925 | -33,824 |
| Depreciation Amortization | 1,061 | 536 | 2,853 | 2,283 | 1,751 |
| Accounts receivable | -3,176 | 1,559 | 5,239 | 3,045 | 1,437 |
| Other Working Capital | -4,733 | 60,389 | 10,947 | 5,847 | 3,801 |
| Other Operating Activity | 6,449 | -64 | 4,276 | 4,681 | 3,380 |
| Operating Cash Flow | $32,160 | $39,493 | $-46,410 | $-35,069 | $-23,455 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | N/A | 1,700 | 1,700 |
| PPE Investments | -92 | -29 | -2,171 | -2,127 | -1,284 |
| Sale Of Investment | 100 | N/A | 1,700 | N/A | N/A |
| Investing Cash Flow | $8 | $-29 | $-471 | $-427 | $416 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,319 | 1,272 | 3,896 | 2,987 | 2,104 |
| Financing Cash Flow | $2,319 | $1,272 | $3,896 | $2,987 | $2,104 |
| Beginning Cash Position | 47,918 | 47,918 | 90,903 | 90,903 | 90,903 |
| End Cash Position | 82,405 | 88,654 | 47,918 | 58,394 | 69,968 |
| Net Cash Flow | $34,487 | $40,736 | $-42,985 | $-32,509 | $-20,935 |
| Free Cash Flow | |||||
| Operating Cash Flow | 32,160 | 39,493 | -46,410 | -35,069 | -23,455 |
| Capital Expenditure | -92 | -29 | -2,171 | -2,127 | -1,284 |
| Free Cash Flow | 32,068 | 39,464 | -48,581 | -37,196 | -24,739 |